Aardvark Therapeutics, Inc. financial data

Symbol
AARD on Nasdaq
Location
4370 La Jolla Village Drive, Suite 1050, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.57K %
Debt-to-equity 9.32 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.8M shares
Common Stock, Shares, Outstanding 21.7M shares
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 21.7M shares +445%
Weighted Average Number of Shares Outstanding, Diluted 21.7M shares +445%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.7M USD +238%
General and Administrative Expense 3.97M USD +287%
Operating Income (Loss) -17.7M USD -248%
Nonoperating Income (Expense) 1.39M USD +52.6%
Net Income (Loss) Attributable to Parent -16.3M USD -290%
Earnings Per Share, Basic -0.75 USD/shares +28.6%
Earnings Per Share, Diluted -0.75 USD/shares +28.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 39.3M USD
Cash, Cash Equivalents, and Short-term Investments 126M USD
Assets, Current 129M USD
Operating Lease, Right-of-Use Asset 439K USD
Other Assets, Noncurrent 3.58M USD
Assets 133M USD
Accounts Payable, Current 4.44M USD
Employee-related Liabilities, Current 2.15M USD
Accrued Liabilities, Current 5.86M USD
Liabilities, Current 10.7M USD
Operating Lease, Liability, Noncurrent 116K USD
Other Liabilities, Noncurrent 0 USD
Liabilities 10.9M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 82K USD
Retained Earnings (Accumulated Deficit) -98.3M USD
Stockholders' Equity Attributable to Parent 122M USD
Liabilities and Equity 133M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD -420%
Net Cash Provided by (Used in) Financing Activities 88.9M USD
Net Cash Provided by (Used in) Investing Activities -113M USD -2252380%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 21.7M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39.3M USD -52.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.2M USD -288%
Operating Lease, Liability, Current 429K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5K USD +150%
Share-based Payment Arrangement, Expense 1.5M USD +942%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares